Tuesday, September 15, 2009 3:37:28 PM
Bio-Rad Helps Raise $1.1 Million in Napa Valley Tour de Cure
HERCULES, CA -- (Marketwire) -- 08/31/09 -- Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, helped raise approximately $1.1 million during the Napa Valley Tour de Cure, which took place on May 3 to benefit the American Diabetes Association.
As the Presenting Sponsor at this year's Napa Valley Tour de Cure, Bio-Rad's "friends and family" team of 146 riders was the largest of the 162 teams participating in the Napa Valley event. Bio-Rad riders raised $73,055, exceeding its total last year of $66,500, setting a new company record. The team was also named one of the Top 10 fundraising teams in the U.S. Bio-Rad also hosted teams in Long Beach, California, and Redmond, Washington. The Tour de Cure is a series of 80 cycling events that occur each year in different locations across the United States.
"Bio-Rad looks forward to Tour de Cure each year," said Bio-Rad President Norman Schwartz. "It is wonderful to see that we exceeded our fundraising goal this year. I'd like to recognize all of the event's participants, all over the U.S. By supporting events such as Tour de Cure, we are helping to improve the lives of those suffering from diabetes."
That is a very nice thing to read, in my humble opinion! I had
a good friend with diabetes...Stockinvestor
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,500 people globally and had revenues exceeding $1.7 billion in 2008. For more information, visit www.bio-rad.com.
For more information, contact:
Bio-Rad Laboratories, Inc.
Tina Cuccia
Corporate Communications Manager
510-724-7000
HERCULES, CA -- (Marketwire) -- 08/31/09 -- Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, helped raise approximately $1.1 million during the Napa Valley Tour de Cure, which took place on May 3 to benefit the American Diabetes Association.
As the Presenting Sponsor at this year's Napa Valley Tour de Cure, Bio-Rad's "friends and family" team of 146 riders was the largest of the 162 teams participating in the Napa Valley event. Bio-Rad riders raised $73,055, exceeding its total last year of $66,500, setting a new company record. The team was also named one of the Top 10 fundraising teams in the U.S. Bio-Rad also hosted teams in Long Beach, California, and Redmond, Washington. The Tour de Cure is a series of 80 cycling events that occur each year in different locations across the United States.
"Bio-Rad looks forward to Tour de Cure each year," said Bio-Rad President Norman Schwartz. "It is wonderful to see that we exceeded our fundraising goal this year. I'd like to recognize all of the event's participants, all over the U.S. By supporting events such as Tour de Cure, we are helping to improve the lives of those suffering from diabetes."
That is a very nice thing to read, in my humble opinion! I had
a good friend with diabetes...Stockinvestor
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,500 people globally and had revenues exceeding $1.7 billion in 2008. For more information, visit www.bio-rad.com.
For more information, contact:
Bio-Rad Laboratories, Inc.
Tina Cuccia
Corporate Communications Manager
510-724-7000
Recent BIO News
- Bio-Rad to Participate in Upcoming Investor Conferences • Business Wire • 05/08/2026 01:00:00 PM
- Bio-Rad Reports First-Quarter 2026 Financial Results • Business Wire • 04/30/2026 08:15:00 PM
- Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026 • Business Wire • 04/16/2026 08:15:00 PM
- Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results • Business Wire • 02/12/2026 09:15:00 PM
- Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026 • Business Wire • 01/29/2026 01:30:00 PM
- Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference • Business Wire • 01/06/2026 01:45:00 PM
- Bio-Rad Reports Third-Quarter 2025 Financial Results • Business Wire • 10/29/2025 08:15:00 PM
- Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025 • Business Wire • 10/16/2025 09:30:00 PM
- Bio-Rad Laboratories, Inc. Co-Founder and Director Emeritus Alice Schwartz Passes Away • Business Wire • 09/30/2025 12:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2025 10:03:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2025 10:03:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2025 10:02:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2025 10:00:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2025 01:00:36 PM
- Bio-Rad's Management to Participate in Upcoming Investor Conferences • Business Wire • 08/25/2025 01:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2025 09:37:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/05/2025 08:47:16 PM
- Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025 • Business Wire • 08/01/2025 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2025 08:17:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2025 08:15:57 PM
- Bio-Rad Reports Second-Quarter 2025 Financial Results • Business Wire • 07/31/2025 08:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/29/2025 09:20:56 PM
- Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations • Business Wire • 07/28/2025 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/28/2025 08:14:54 PM
